Trending
Tokyo stocks open higher on AI, tech gains after strong Micron earningsChina’s JCET to build new plant in Shanghai to expand advanced chip packagingJNJ International Co., Ltd. to Strengthen North American Market Presence at AAPEX Expo 2026 Las VegasEurope is pushing back on Washington's chip warDelayed N1trn Stabilisation Fund deepens credit crisisQuantum computers will supercharge the worldScreenworks appoints Lisa Rose as CEOGoogle's new payment policies are a preview of what could come to Apple platformsStar Fox's day one update detailed (UPDATE)Forward Sioux Falls Helps Fill the Gap, Provides Augustana Social Work Students With Paid InternshipsB.C. teacher accepts 10-year ban over inappropriate relationship with studentNY Fed's Marchioni calls new FOMC reserves language cleanup, not a Warsh policy shiftElectricity: 655m still in darkness as WHO, partners warn of Global Energy, health crisisorder goes live on SmythsMattel’s Hot Wheels rakes in $2.5b as adult collectors take overThese Xgimi Home Projectors Are a Steal With Our Exclusive Prime Day Discount CodesTokyo stocks open higher on AI, tech gains after strong Micron earningsChina’s JCET to build new plant in Shanghai to expand advanced chip packagingJNJ International Co., Ltd. to Strengthen North American Market Presence at AAPEX Expo 2026 Las VegasEurope is pushing back on Washington's chip warDelayed N1trn Stabilisation Fund deepens credit crisisQuantum computers will supercharge the worldScreenworks appoints Lisa Rose as CEOGoogle's new payment policies are a preview of what could come to Apple platformsStar Fox's day one update detailed (UPDATE)Forward Sioux Falls Helps Fill the Gap, Provides Augustana Social Work Students With Paid InternshipsB.C. teacher accepts 10-year ban over inappropriate relationship with studentNY Fed's Marchioni calls new FOMC reserves language cleanup, not a Warsh policy shiftElectricity: 655m still in darkness as WHO, partners warn of Global Energy, health crisisorder goes live on SmythsMattel’s Hot Wheels rakes in $2.5b as adult collectors take overThese Xgimi Home Projectors Are a Steal With Our Exclusive Prime Day Discount Codes

Health Canada approves drug that treats sleep apnea in adults with obesity

Zepbound the now the only GLP-1 drug in Canada approved for the sleep disorder that causes people to stop breathing temporarily because their upper airway is blocked....

News Desk

Staff Writer

Published

Jun 25, 2026

Source

Global News

Analytics

0 0 0
Health Canada approves drug that treats sleep apnea in adults with obesity

AI Insight:This approval marks a significant breakthrough in the treatment of sleep apnea for adults with obesity.

Health Canada has granted approval for Zepbound, a glucagon-like peptide-1 (GLP-1) receptor agonist, to treat sleep apnea in adults with obesity. Zepbound is now the only GLP-1 drug in Canada approved for this sleep disorder, which causes people to stop breathing temporarily due to their upper airway being blocked. This condition can lead to fragmented sleep, daytime fatigue, and increased risk of cardiovascular disease. The approval of Zepbound provides a new treatment option for adults with obesity who suffer from sleep apnea, offering hope for improved sleep quality and overall health. The approval was based on clinical trials demonstrating the efficacy and safety of Zepbound in reducing the severity of sleep apnea in this population.